Preliminary revenue from biopharma and other customers is estimated to be $15.8 million in the fourth quarter of 2022 compared with $15.4 million in the fourth quarter of 2021, and preliminary revenue from biopharma and other customers includes estimated revenue from Natera at $8.2 million in the fourth quarter of 2022. Interim CEO Aaron Tachibana says: "We ended 2022 by exceeding our previous full year guidance range, driven by oncology revenue growth of 42% for the fiscal year. We will be providing details in the coming weeks about extending our cash runway while focusing on our key product opportunities."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PSNL: